Patiromer submitted to EMA to seek approval in the EU
Monday, 25 April 2016, ↓ directly to download
Vifor Fresenius Medical Care Renal Pharma submits marketing authorisation application requesting European approval of Patiromer for treatment of hyperkalemia
Vifor Fresenius Medical Care Renal Pharma has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for Patiromer. The company is seeking approval of Patiromer for the treatment of hyperkalemia, or elevated blood potassium levels, in the European Union (EU) through the EU centralized procedure.
In August 2015, Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a common company of Galenica and Fresenius Medical Care, and Relypsa, Inc. entered into an exclusive partnership to commercialise the potassium binder Patiromer in Europe and additional territories.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
Friday, 23 December 2016
Friday, 9 December 2016
Monday, 28 November 2016
Thursday, 6 October 2016
Friday, 2 September 2016
Head of Corporate Communications
Head Investor Relations